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Summary
Brain metastases are treated with surgery, radiotherapy,
radiosurgery, and chemotherapy. In this review, recently
published studies concerning different treatment strate-
gies are presented with respect to solitary lesions, multiple
metastases, and recurrent tumor growth. Selection criteria
for the appropriate therapy are: control of the 
primary tumor, extent of extracerebral metastases, time
interval between diagnosis of the primary tumor and the
development of cerebral lesions, number of cerebral me-
tastases, Karnofsky performance scale score, and age. 
Treatment approaches were evaluated with respect to
median survival time and quality of life.
A singular brain metastasis can be treated with surgery or
with radiosurgery. Especially when the primary tumor is
under control, there are few extracerebral lesions which
are stable, the Karnofsky performance scale score is above
70, the lesion is larger than 3 cm in diameter and surgically
accessible surgery is the treatment of choice. Postopera-
tive adjuvant radiotherapy may delay relapse. Median sur-
vival time ranges between 10 to 18 months. Radiosurgery
can be applied in lesions smaller than 3 cm in diameter
and is the treatment of choice in lesions which are surgi-
cally not accessible. Multiple metastases are treated either
by conventional radiotherapy, radiosurgery or surgery.
Commonly, no more than 3 lesions are approached by 
either surgery or radiosurgery. Median survival time 
ranges between 6 to 9 months for both treatment con-
cepts, but without therapy only is 4–6 weeks. According to
the clinical and neurological condition of the patient, recur-
rent brain metastases can be treated by operation, reirra-
diation, or radiosurgery. The efficacy of chemotherapy
depends on the chemosensitivity of the primary tumor and
the ability to penetrate the blood-brain barrier. Long-term
survivors with cancer disease encourage to perform active
treatment strategies.
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Zusammenfassung
Hirnmetastasen werden durch Operation, Ganzhirnbe-
strahlung, Radiochirurgie und Chemotherapie behandelt.
In dieser Übersichtsarbeit werden kürzlich publizierte Stu-
dien bezüglich der Therapiekonzepte für solitäre Läsionen,
multiple Metastasen und Tumorrezidive vorgestellt. Aus-
wahlkriterien für eine angemessene Behandlung sind:
Kontrolle des Primärtumors, Ausmaß der extrakraniellen
Metastasen, Zeitintervall zwischen Diagnose des Primär-
tumors und dem Auftreten der Hirntumoren, Anzahl der
zerebralen Metastasen, Karnofsky-Performance-Scale-
Score und Lebensalter. Behandlungskonzepte wurden
nach der medianen Überlebenszeit und Lebensqualität
ausgewertet. Singuläre Hirnmetastasen können operativ
oder radiochirurgisch behandelt werden. Insbesondere
wenn der Primärtumor unter Kontrolle ist, wenige extra-
zerebrale Läsionen bestehen und diese stabil sind, der
Karnofsky-Performance-Scale-Score über 70 ist, die Tumo-
ren größer als 3 cm im Durchmesser und chirurgisch
erreichbar sind, ist die Operation die Methode der Wahl.
Postoperative adjuvante Strahlentherapie kann erneute
Progression verzögern. Die mediane Überlebenszeit liegt
zwischen 10 und 18 Monaten. Für Läsionen, die kleiner als
3 cm sind und chirurgisch nicht erreicht werden können, ist
die Radiochirurgie die Therapie der Wahl. Multiple Meta-
stasen können durch konventionelle Ganzhirnbestrahlung,
Radiochirurgie oder Operation behandelt werden. Im all-
gemeinen werden nicht mehr als 3 Herde operativ oder
radiochirurgisch angegangen. Die mediane Überlebenszeit
liegt bei beiden Therapieformen zwischen 6 und 9 Mona-
ten, ohne Behandlung hingegen bei nur 4–6 Wochen. Ent-
sprechend dem klinischen und neurologischen Zustand
der Patienten können Rezidive von Hirnmetastasen durch
chirurgische Entfernung, erneute Bestrahlung oder durch
Radiochirurgie therapiert werden. Die Wirkung der Chemo-
therapie hängt von der Chemosensitivität des Primärtu-
mors und der Durchlässigkeit der Blut-Hirn-Schranke für
das Chemotherapeutikum ab. Langzeitüberleber motivie-
ren zu aktiven Behandlungsstrategien.
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Introduction
Metastases to the brain occur in approximately 20–40% of all
patients with carcinoma [1, 2] and comprise more than 30% of
all brain tumors. Most cerebral metastases originate from  pri-
mary lung tumors in 25%, from breast tumors in 21%, and
from malignant melanoma in 10–15%. Autopsy data reveal
that almost 70–90% of all patients with malignant melanoma
develop cerebral lesions [3].At the time of diagnosis more than
50% of the patients present with multiple lesions. There is a
rising incidence of brain metastases, since advanced treatment
strategies for extracerebral cancer prolong patient’s survival
and allow for development of brain metastases [4].
The goal in treating brain metastases is to eliminate the life-
threatening brain lesion that raises intracranial pressure and
causes neurological deficits. Because brain metastases usually
occur in the final stage of cancer, patients face reduced life
expectancy. The median survival time without treatment 
ranges between 1 and 3 months [5, 6]. One of the major aims in
treating these patients is to maintain or to improve their quali-
ty of life. Many treatment modalities have been applied during
recent years. Prognostic factors have been evaluated that are
associated with prolonged survival of patients. Here we review
current treatment strategies according to recently published
studies.
Diagnosis
Initial neurological symptoms of brain metastases include
headaches, seizures or neurological deficits, e.g. hemiparesis,
aphasia or hemianopsia. Mass effects lead to symptomatic ele-
vated intracranial pressure with headaches, dizziness, vomiting,
drowsiness and finally loss of consciousness. The diagnosis is
usually made by cerebral computed tomography (CT) or
magnetic resonance imaging (MRI). The typical diagnostic
image on contrast-enhanced CT and T1-weighted MRI resem-
bles a garland-like ring with central necrosis [7]. Very small
lesions of less than 1 cm in diameter can be detected by T2-
weighted MRI, demonstrating an edematous alteration of the
parenchyma. MRI has to be applied on a routine basis in pre-
operative diagnosis of cerebral metastasis [8, 9]. Additional
lesions may be detected that have not been visualized by CT
scan. The sensitivity of MRI can be enhanced by high-dose
application of contrast media [10, 11], by the interval of time
between i.v. injection of contrast media and imaging, and by
the field strength of the scanner. The diagnosis of multiple
cerebral metastases is crucial for further treatment decisions.
Brain metastases of certain origin, e.g. from melanoma or
hepatocellular carcinoma, tend to cause hemorrhage. The 
sudden onset of symptoms leads to differential diagnostic con-
siderations, including spontaneous intracerebral hemorrhage
without association with neoplastic disease. Murakami et al.
[12] presented a series of 16 cases of hepatocellular carcinomas
with brain metastases. Eight of these patients suffered from
apoplexy-like symptoms; in 14 patients a hemorrhage had
occurred.The authors point out the value of contrast-enhanced
CT or MRI scan to differentiate between bleeding and tumor-
associated bleeding.
In a prospective study by van de Pol [13] the question was 
raised whether primary staging of asymptomatic small-cell
lung cancer patients should routinely include an MRI scan of
the brain. The results of this study indicate that most patients
develop clinical symptoms leading to the diagnosis of a ce-
rebral lesion and that the routine scan of the brain rarely
detects metastases at an early state. This study addresses the
important question whether tumor staging in cancer patients
has to include brain examination on a routine basis at least in
primaries which tend to seed in the brain. Considering the
development of metastases in functionally silent areas of the
brain or as very small asymptomatic lesions, they might be un-
detected, although their detection will greatly influence treat-
ment strategies (see below).
Microneurosurgical Therapy of a Single 
Brain Metastasis
In recent years, several studies have provided evidence that
surgical excision of a brain metastasis optimizes quality of life
and prolongs survival time. In a randomized prospective study
by Patchell et al. [14], the efficacy of surgery plus WBRT
(Whole-Brain Radiation Therapy) versus radiotherapy alone
was investigated. Only single brain metastases were included.
The results of the study indicate that patients with a single
brain metastasis who receive treatment with surgical resection
plus radiotherapy live longer, have fewer recurrences and a
better quality of life than those who have been treated only by
radiotherapy. In 1992 Smalley et al. [15] evaluated 229 cancer
patients with solitary cerebral lesions. All patients underwent
craniotomy and part of them adjuvant WBRT. Prognostic fac-
tors for the survival time were the extent of systemic disease
and gross total removal of cerebral lesions. Patients without
systemic disease and total extirpation of brain metastasis had 
a median survival time of 1.3 years. Patients with systemic
disease and subtotal tumor removal had a median survival of
5.3 months only. Adjuvant radiotherapy was associated with
improved survival time. Delarive and de Tribolet [16] reported
on 81 patients with brain metastases of different origin. All
patients were treated by surgery and most of them received
postoperative WBRT. The mean survival was 10.2 months. Ten
patients survived more than 18 months, 1 patient more than 4
years. Long-term survivors (up to 10 years), even with brain
metastases, are known from the literature [17, 18]. Prognostic
factors were solitary brain lesions, no extracerebral tumor 
burden, control of the primary tumor, high Karnofsky perfor-
mance score and total surgical resection of the cerebral lesion,
in most cases accompanied by adjuvant radiotherapy.
In 100 patients with colorectal cancer and brain metastases, the
course of disease was studied with respect to single treatment
strategies [5]. The different regimens included: surgery, radio-
therapy alone, and steroids only. Most patients suffered from
additional liver or lung metastases. The mean survival time for
patients treated with steroids was 1 month, with radiotherapy
alone 3 months, and with surgery alone 9 months. The authors
found that the extent of extracerebral metastases did not
necessarily lower life expectancy. However, a short interval
between the development of the primary tumor and the ap-
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pearance of cerebral metastases worsened the prognosis sig-
nificantly.
Today, there is little doubt that single brain metastasis should
be surgically removed whenever possible [4, 6, 19]. The opera-
tive technique of metastasis surgery is routine. Metastatic 
lesions are usually well circumscribed and show demarcation
from the surrounding brain tissue. Small lesions can be ap-
proached by neuronavigation. Areas of functional importance
can be preserved.
Microneurosurgical Treatment of Multiple 
Cerebral Metastases
Treatment of multiple brain metastases ranges from supportive
care to conventional radiotherapy, chemotherapy, radio-
surgery, and surgical management [20–23]. There is no doubt
that the development of multiple metastases implies a fatal
prognosis. Surprisingly, patients with multiple metastases can
be unimpaired, without significant neurological symptoms.
These patients ask for active help. Conventional radiotherapy
plays the most important role in treatment of multiple me-
tastases [24]. However, the technical progress in recent years
offers additional surgical and radiosurgical methods in treating
these patients. In 1993 Bindal et al. [23] presented a review on
56 patients with multiple brain metastases who underwent sur-
gery. In these patients all brain lesions were resected. The
median survival time averaged about 14 months. Nussbaum et
al. [25] published a study evaluating 729 patients with respect
to histology, multiplicity, surgery, and survival. A total of 384
patients presented with a single and 345 with multiple brain
metastases. The shortest time interval between diagnosis of 
the primary tumor and appearance of brain metastases 
was observed in non-small-cell lung cancer (NSCLC), being 
3 months, and the longest in patients with breast cancer, being
53 months. The median survival for patients with a single me-
tastasis treated by surgery was 11 months, and without surgery 
3 months. In this study, surgery did not influence survival in
patients with multiple metastases. Wronski et al. [26] reported
on 231 patients with NSCLC. Subsequent to surgery, median
survival time was 11 months. Patients with single metastases
survived longer than those with multiple lesions (11.1 vs. 8
months). The conclusion from these studies and others [27, 28]
demonstrates that patients with multiple cerebral lesions have
a poor prognosis, but might still profit from surgical interven-
tion. Again prognostic factors, e.g. systemic disease, the extent
of extracerebral tumor burden, the amount of resection, the
location of the lesions, and the Karnofsky performance scale
score, are of great importance for the prognosis of the patient.
Nowadays, operations in neurosurgery are routinely per-
formed employing neuronavigation. With this method one can
resect brain metastases at different sites after optimal planning
of the approaches. Small targeted craniotomies are performed
for the excision of brain lesions. During the last few years, in
our department patients with multiple cerebral metastases (up
to four lesions at different sites) have been operated on in one
session (fig. 1a–g). The advantage for the patients was that all
cerebral lesions were removed in one operation and the dura-
tion of hospitalization was no longer than for patients with
single brain metastasis. One important criterion for this man-
agement was the preservation of quality of life, which should
not be worsened by operative approaches.
Radiotherapy 
Conventional WBRT alone is the most common treatment for
patients with brain metastases. Median survival ranges from 
3 to 6 months [24, 29, 30]. WBRT has been the mainstay of 
treatment since the 1950s. The standard treatment regimen is 
10 · 3 Gy in 2 weeks, appropriate treatment varies depending
on radiotherapeutic practices. Trials conducted by the Radia-
tion Therapy Oncology Group (RTOG) indicate that doses
ranging from 20 Gy over 1 week to 50 Gy over 4 weeks dem-
onstrate no significant difference in neurological control of 
disease or length of survival, but that doses <20 Gy are less ef-
fective [30, 31]. Additional focal radiation to the tumor site has
no better results than WBRT alone [32]. Large retrospective
studies have shown that more than half of these patients 
treated with WBRT die from extracerebral tumor progression
[2, 33].
Accelerated and hyperfractionated radiation schedules have
been evaluated in several studies of the RTOG. In a ran-
domized phase III study of accelerated hyperfractionation of
patients with nonresected brain metastases (1.6 Gy b.i.d. to a
total dose of 54.4 Gy vs. an accelerated fractionation of 30 Gy
in 10 daily fractions) no treatment advantage could be found in
the accelerated hyperfractionated group. Therefore, results
reported from a previously RTOG phase I/II study [34] could
not be confirmed [35].
It is still controversial as to whether adjuvant radiotherapy
must follow after total extirpation of a solitary cerebral me-
tastasis. Reasons advocating adjuvant radiotherapy are:
1. The incidence of local relapse may be increased in patients
without adjuvant radiotherapy.
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Fig.1.a. Three-dimen-
sional imaging of 3 ce-
rebral metastases by
neuronavigation.
2. Small tumor cell clumps not visible by MRI at other sites can
be destroyed by WBRT.
Reasons for rejecting radiotherapy are:
1. Brain metastases are usually well defined and can be extir-
pated completely.
2. Radiotherapy can be preserved for recurrent tumor growth.
Several investigators evaluated the efficacy of WBRT in addi-
tion to surgery versus WBRT alone [5, 14–16, 36–39]. To date,
the overall results of surgical treatment strategies plus adju-
vant WBRT indicate that WBRT alone as treatment is inferior
to the combined treatment [5, 14]. Whenever possible, surgical
extirpation should be performed. Postoperative radiotherapy,
although questionable, may result in a smaller portion of brain
relapse and a higher percentage of patients remaining disease-
free [38]. The results of a prospective randomized study to 
evaluate the efficacy of surgery plus WBRT versus surgery
alone are still pending.
In multiple cerebral metastases WBRT alone or in combina-
tion with radiosurgery is the favorable treatment [24, 28–31,
40–42]. In radiosensitive tumors,e.g. small-cell lung cancer [43],
Treatment Strategies in Brain Metastases 101Onkologie 2000;23:98–104
Fig. 1. b–d. MRI T1-weighted volume scan showing 3 brain metastases preoperatively.
Fig. 1. e–g. Postoperative MRI control with contrast media. The patient was treated postoperatively with 30 Gy whole-brain radiotherapy.
WBRT alone is the treatment of choice. Age was evaluated as
an important factor for the prognosis of patients with cerebral
metastasis. Nieder et al. [44] reported on 35 patients older than
70 years of age. The patients received 30 Gy WBRT and were
treated with corticosteroids. Six patients received lower or
higher total doses with 50.4 Gy at maximum. The median sur-
vival time of all patients who completed radiotherapy was 
67 days. Patients with extracerebral metastases had a median
survival of 31 days. The Karnofsky performance score was the
most important prognostic factor.The poor results of this study
again reveal the importance of age as prognostic factor.
In some studies, prophylactic cranial irradiation (PCI) has
been discussed as prevention for the development of brain
metastasis in small-cell lung cancer.The results of these studies
[45–48] indicate that the frequency of cerebral seeding is re-
duced, but not prevented. The brain metastasis-free survival
seems to be prolonged.
Long-term ill effects of radiotherapy are usually not a signifi-
cant issue in the treatment of brain metastases because of the
short survival of the patients. Short-term effects are nausea,
vomiting, headaches, alopecia, and in some cases fever. In long-
term survivors ataxia, urinary incontinence, or even dementia
might occur [49, 50].
Radiosurgery
Many publications deal with the results of radiosurgery for
single and multiple brain metastases [41, 42, 51–60]. Stereotac-
tic radiosurgery by gamma knife or linear accelerator is judged
to be as effective as surgery. The applied doses range between
18 and 20 Gy. In 1987 Sturm et al. [61] described a shrinkage of
metastases, reduction of cerebral edema and an improvement
in clinical conditions in patients treated radiosurgically by line-
ar accelerator. This was confirmed by others [42, 51]. The main
domain for radiosurgery are small and deep-situated lesions
that cannot be approached by surgery. However, the limitation
for radiosurgery is size and number of lesions. Alexander et al.
[54] reported on 248 patients with 421 lesions treated with a 
6-Me V linear accelerator. Patients with a Karnofsky perfor-
mance score less than 70, evidence of acute neurological dete-
rioration, and tumors larger than 4 cm in diameter were ex-
cluded. The median treatment dose was 1,500 cGy. WBRT was
applied in all newly diagnosed patients. The study [54] showed
a median survival time of 9.4 months. Prolonged survival 
was observed in the absence of systemic disease, age younger
than 60 years, maximally 2 cerebral lesions, and female sex.
Actuarial local control rates were 85% at 1 year and 65% at 
2 years. Factors associated with a significantly reduced local
control rate were location below the tentorium and large
tumor volume.The suitability of radiosurgery using the gamma
knife was demonstrated by Kida et al. [53]. Cerebral metas-
tases from primary tumors of different origin were treated 
with doses ranging from 12 to 25 Gy (mean 18.9 Gy). A tumor
control rate of 98.2 and 96.6% was reported after 3 and 
6 months, respectively. In a multiinstitutional U.S. study the
outcome and prognostic factors subsequent to radiosurgery
plus WBRT of single brain metastasis were evaluated [62].
Radiosurgery was performed with a linear accelerator ap-
plying a median dose of 17 Gy. In WBRT patients received a
median dose of 37.5 Gy. 122 patients were treated. The overall
local control rate was 86%; the actuarial median survival time
after radiosurgery was 56 weeks. The influence of number of
lesions on survival was emphasized by Joseph et al. [57]. Sur-
vival was equivalent for patients with 1 or 2 lesions to patients
with a solitary metastasis treated by surgical resection and
WBRT. Survival after radiosurgery for 3 or more lesions was
similar to that reported for whole-brain irradiation.
Radiosurgery versus surgery in terms of costs, hospitalization,
morbidity, and wider applicability has been discussed by sever-
al authors [60, 63]. Since similar results are reported in radio-
surgery and surgery, the cost effectiveness for radiosurgery
seems to be more favorable. However, these considerations
omit the fact that cerebral lesions should be classified by his-
tology prior to radiotherapeutic treatment. Even if the primary
tumor is known, cerebral lesions cannot be classified as me-
tastases by MRI scan without any doubt [64]. Therefore, the
patient has to undergo stereotactic biopsy, which mandates
hospitalization at least for a short time. Both treatment modal-
ities can be applied in lesions smaller than 3 cm in diameter,
whereas in larger tumors only surgical extirpation is possible.
Treatment of Recurrent Brain Metastases
The final problem in treating brain metastases is the question
of recurrent tumor growth. General opinion supports the deci-
sion for active treatment depending on the Karnofsky perfor-
mance score of the patient, the extent of extracerebral me-
tastases, and the interval of time between the last treatment
and the recurrence of the lesions. Bindal et al. [65] evaluated 
48 patients who developed recurrent brain metastases. Median
survival time from first craniotomy to diagnosis of recurrence
was 6.7 months. Median Karnofsky performance score prior to
reoperation was 80. Median survival time after reoperation
was 11.5 months. In a multivariate analysis, favorable prog-
nostic factors were defined: no systemic disease, Karnofsky
score above 70, time to recurrence more than 4 months,
age above 40 years, primary tumor site with the exception of
breast cancer and malignant melanoma. In cases of second
recurrence, reoperation was considered. The median survival
time averaged about 8.6 months versus 2.4 months for patients
who did not undergo a second reoperation. These data were
confirmed by Arbit et al. [66] when evaluating 109 patients
with recurrent brain metastases of NSCLC. Sawaya et al. [37]
stated that whenever possible surgery should remain the treat-
ment of choice, even in recurrent brain metastases.
Wong et al. [67] reported on 86 patients who were reirradiated
for progressive brain metastases. All patients had received 
30 Gy WBRT previously. The median dose of the second 
course was 20 Gy. The median survival time averaged about 
4 months; in most cases neurological improvement occurred.
The effectiveness of stereotactic radiosurgery for recurrent
brain metastases has been investigated in many studies [41, 54,
68, 69]. Breneman et al. [41] treated 79 patients with recurrent
tumor growth by radiosurgery. All of these patients had re-
ceived WBRT before. The applied doses ranged between 
16 and 18 Gy. The median survival for the entire group was 
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43 weeks from the date of radiosurgery and 71 weeks from the
day of original diagnosis of brain metastases. This study and
other extirpations [41, 57, 68] confirmed that patients with up
to 2 cerebral metastases, but without active extracerebral
tumor burden, showed prolonged survival time due to the
applied treatment. In a study protocol of the Radiation Onco-
logy Group, the effectiveness of radiosurgery was investigated
with respect to tumor volume and recurrent cerebral metas-
tases. A total of 102 patients were enrolled, of whom 64 had
recurrent brain metastases and were irradiated prior with a
dose of 30 Gy. Multivariate analysis revealed that a tumor
volume of 8, 200 mm3 or more is one of the limiting factors in
treating patients with recurrent tumors by radiosurgery subse-
quent to previous irradiation [69].
Taken together, recurrent brain metastases can be approached
either by surgery, radiosurgery, or second conventional radio-
therapy. Depending on the Karnofsky performance scale, the
extent of extracerebral tumor burden, and the time interval be-
tween the first cerebral metastasis and the recurrence (which
should be more than 5 months), a decision must be made as to
whether the patient will be treated surgically or not. Patients in
good clinical conditions might profit from surgery. Radiosur-
gery offers an alternative treatment strategy. Even after pre-
vious radiotherapy, radiosurgery can be applied, although the
risk for radiation-induced necrosis is increased. The expected
median survival time for patients ranges from 6 to 12 months.
In addition, a second course of conventional radiotherapy 
can be considered for some patients, since the routinely used
dosage of 30 Gy allows for a second radiotherapy course.
Chemotherapy
Chemotherapy has its implication in the treatment of cerebral
metastases. The tumor of origin determines the selection of
chemotherapeutic agents. However, it has been shown that
chemosensitivity from brain metastases can differ from the pri-
mary tumor [70]. The prerequisite for adjuvant chemotherapy
is the maximal reduction of tumor burden by surgery. Many
studies have been published with respect to chemotherapeutic
trials of different carcinomas. Combined treatment strategies –
radiotherapy and chemotherapy – are favored [71–74]. One of
the major points in advocating chemotherapy is the simul-
taneous treatment of cerebral metastases and extracerebral
tumor burden. Since cancer is an ongoing disease in which cells
constantly separate from tumor lesions and circulate in the
bloodstream, the risk for metastatic seeding at different sites is
high. Systemic involvement of the disease mandates systemic
chemotherapy. The blood-brain barrier (BBB) does not allow
the entrance of most of the chemotherapeutic agents into the
brain [75]. Whereas lipophilic substances can penetrate the
BBB easily, hydrophilic substances do not. In tumors the BBB
is not totally intact. This is called blood-tumor barrier (BTB).
The BTB allows the entrance of some additional chemothera-
peutic agents, which normally do not gain access to the brain.
Furthermore, opening of the BBB with hyperosmotic sub-
stances or bradykinine is possible [76, 77]. The complexity of
cancer disease and chemotherapy demands the expertise of
specialists.
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